Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Novacyt    ALNOV   FR0010397232


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Novacyt : Information mensuelle sur le contrat de liquidité et sur le nombre total de droits de vote 4 jan 2021

01/04/2021 | 09:40am EDT

Novacyt S.A.

("Novacyt" or the "Company")

Liquidity Agreement Monthly Update and

Total Voting Rights

Paris, France and Camberley, UK - 4 January 2021 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the "Liquidity Agreement"). The Liquidity Agreement is governed by French law and is further summarised in the 'notes for editors' section below.

During the period from 1 December to 31 December 2020, Invest Securities purchased 4,897 ordinary shares at a maximum price of €9.85 and a minimum price of €7.83 and sold 7,647 ordinary shares at a maximum price of €10.30 and a minimum price of €8.30 under the Liquidity Agreement. The total number of ordinary shares in the Company, which are held in treasury as at close of business on 31 December 2020, is 3,072.

Total Voting Rights

The total number of ordinary shares in the Company is 70,626,248. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company's Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.

For further information, please refer to www.novacyt.comor contact:

Novacyt SA

Graham Mullis, Chief Executive Officer Anthony Dyer, Chief Financial Officer +44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker) Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470 0470

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw / Mary Whittow +44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com/ Alex.Shaw@fticonsulting.com/ mary.whittow@fticonsulting.com

FTI Consulting (France) Arnaud de Cheffontaines +33 (0)147 03 69 48 arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

Further information on the Liquidity Agreement

On 12 September 2016, the Company and Invest Securities entered into the Liquidity Agreement pursuant to which Invest Securities provides liquidity services in relation to the ordinary shares to the Company. Invest Securities may purchase ordinary shares on behalf of the Company under the agreement, subject to approval from Shareholders as to the price at which ordinary shares can be brought back and the aggregate amount that the Company may provide to Invest Securities to purchase such ordinary shares.

Shareholder approval was granted at the Shareholders' meeting held on 29 September 2020 for the purchase of ordinary shares by Invest Securities under the agreement at a maximum purchase price per ordinary shares of €12.00 for an aggregate maximum purchase price of €200,000 and for 18 months from the date of the approval. Under the agreement, Invest Securities must act completely independently of the Company and the Company must not communicate with the employees of Invest Securities who are responsible for performing the agreement. Invest Securities is paid €10,000 per annum for its services under the liquidity agreement. The agreement has an initial term of two years, with a rolling extension of one year thereafter. The agreement can be terminated by either party at the end of each such period subject to two months' prior notice. The Liquidity Agreement is governed by French law. Ordinary shares purchased by Invest Securities are either cancelled or held as treasury shares (which are non-voting and do not rank for dividends).


Novacyt SA published this content on 04 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 January 2021 14:39:07 UTC

© Publicnow 2021
All news about NOVACYT
03/24NOVACYT  : to Launch Test For COVID-19 Variants of Concern
03/24NOVACYT S.A. ("NOVACYT", THE "COMPAN : Launch of CE-Mark test to detect multiple..
03/17NOVACYT  : Launches Mobile Processing Laboratories For On-Site Rapid COVID-19 Te..
03/17NOVACYT S.A. ("NOVACYT", THE "COMPAN : Launch of Mobile Processing Laboratories ..
02/24NOVACYT S.A. :  Research and Development Update
02/02NOVACYT  : Launches New Tests to Diagnose Latest COVID-19 Variants; Shares Rise ..
02/02NOVACYT  : Rolls Out New Product For Detection Of COVID-19 Variants
02/02NOVACYT S.A. :  Launch of PCR Genotyping Assay Portfolio to Detect COVID-19 Vari..
01/29NOVACYT  : FY20 Revenue Soars 20x On COVID-19 Product Sales; Shares Down 6%
01/29NOVACYT S.A. : Full Year 2020 Trading Update
More news
Sales 2020 312 M 371 M 371 M
Net income 2020 183 M 218 M 218 M
Net cash 2020 41,3 M 49,2 M 49,2 M
P/E ratio 2020 2,03x
Yield 2020 -
Capitalization 330 M 393 M 393 M
EV / Sales 2020 0,93x
EV / Sales 2021 1,38x
Nbr of Employees 110
Free-Float 99,3%
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 2
Average target price 4,90 €
Last Close Price 4,67 €
Spread / Highest target 22,0%
Spread / Average Target 4,88%
Spread / Lowest Target -12,2%
EPS Revisions
Managers and Directors
Graham David Mullis Chief Executive Officer & Executive Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Lisa Henriet Director-Group Operations
Andrew John William Heath Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.34.89%56 442
WUXI APPTEC CO., LTD.-1.48%45 479